Delivery of Third Milestone and Grant of Options

Kromek secures $2.5m milestone payment; final $5m due by April 2029.

Risk flags

• ●Execution risk is significant, as the final $5.0m payment depends on successful delivery of the remaining contractual obligations by April 2029. Delays or failure to meet milestones could defer or jeopardize this payment.
• ●Disclosure risk is present: the announcement omits key financial metrics such as revenue, profit, cash flow, and does not detail the broader impact of the Enablement Agreement on the company’s financial health. This limits investor visibility into underlying performance and sustainability.
• ●Concentration risk arises from the heavy emphasis on a single agreement with Siemens Healthineers. The lack of information on other revenue streams or diversification suggests that company fortunes may be closely tied to this contract’s execution and completion.

Bottom line

This update confirms Kromek’s progress on a major contract, with $32.5m received and a final $5.0m due by April 2029, but provides no information on profitability, cash flow, or the company’s wider financial position. The focus on executive options signals management alignment with milestone delivery, but the absence of detail on the bonus structure and immediate vesting terms leaves gaps in incentive clarity. Investors have no visibility into operational performance outside this agreement, making it difficult to assess the company’s resilience or growth prospects. To materially strengthen the investment case, Kromek would need to disclose comprehensive financials and clarify how this contract fits into its broader business. The key takeaway: milestone payments are on track, but the company’s overall financial health remains opaque.

Announcement summary

(AIM: KMK) Kromek Group plc announced the successful delivery of the third milestone under its Enablement Agreement with Siemens Healthineers, resulting in the receipt of the third payment instalment of $2.5m. To date, the Company has received $32.5m under the Enablement Agreement, with a remaining payment of $5.0m payable at completion of the Group's delivery, which is expected to occur in the financial year to 30 April 2029. On 5 August 2026, Kromek granted 555,687 options each to Arnab Basu (CEO) and Berry Beumer (COO and President of the Advanced Imaging Division), with an exercise price of 1p per Ordinary Share. The number of options was calculated based on a price of 5.65p per Ordinary Share, being the average price on AIM for the three months preceding and following the announcement of the Siemens Healthineers transaction on 30 January 2025. Following this grant, the Company has options and long-term incentive awards outstanding over a total of 76,486,278 Ordinary Shares, representing 11.7% of the Company's issued share capital. The company projects that completion of the Enablement Agreement and receipt of the final payment will occur in the financial year to 30 April 2029.

Disagree with this article?